Fludarabine
Precursor B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)Small moleculePhase 2/3Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Precursor B-Cell Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Blinatumomab Amgen | Phase 3 | BBB |
Cyclophosphamide Princess Maxima Center for Pediatric Oncology | Phase 2/3 | BB |
Cytarabine Princess Maxima Center for Pediatric Oncology | Phase 2 | B |
Methotrexate First Affiliated Hospital of Zhejiang University | Phase 2 | B |
Pegaspargase First Affiliated Hospital of Zhejiang University | Phase 2 | B |
View all 27 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative · Phase 2
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →